---
title: Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support
nct_id: NCT01967602
overall_status: UNKNOWN
sponsor: National Taiwan University Hospital
study_type: OBSERVATIONAL
primary_condition: ARDS
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01967602.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01967602"
ct_last_update_post_date: 2013-10-23
last_seen_at: "2026-05-12T06:25:03.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support

**NCT ID:** [NCT01967602](https://clinicaltrials.gov/study/NCT01967602)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 70
- **Lead Sponsor:** National Taiwan University Hospital
- **Conditions:** ARDS, Multi-organ Failure
- **Start Date:** 2011-10
- **Completion Date:** 2015-04
- **CT.gov Last Update:** 2013-10-23

## Brief Summary

The goal of this project is to find a marker expression that the investigators can use to trace symptom progression and develop a more efficient therapy to enhance ARDS patient survival rate and better post-ICU life quality.

## Detailed Description

The investigators will first identify acute respiratory distress syndrome (ARDS) patients receiving ECMO support in ICU at National Taiwan University Hospital, and then collect blood, urine and bronchioalveolar lavage fluid (BALF) samples at different time points: before setting up ECMO, 2, 6, 12, 24, 72 hours,5 and 14 days after ECMO installment, time to wean ECMO and the day removing ECMO and leaving ICU. From the samples, the free radicals, cytokines (IL-1, IL-6, IL-8, IL-18,tumor necrosis factor-α, transforming growth factor-β), and inflammasome- related markers, immune cell responses and other biochemical markers would be measured. The novel biomarkers to predict the outcome of the patient will be identified.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. \>18 years old
2. ARDS, needing ECMO support

Exclusion Criteria:

1. pre-existing sepsis
2. pre-existing chronic renal failure (dialysis dependent), liver failure other diseases precluding chance of survival.
```

## Primary Outcomes

- **Mortality or multi-organ failure** _(time frame: 7 days)_ — Patients who survived for more than 7 days after ECMO treatment were defined as survival, and non-survival patients were defined as expired or multiple organ failure incompatible with life within 7 days after ECMO installation.

## Locations (1)

- National Taiwan University Hospital, Taipei, Taiwan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national taiwan university hospital|taipei||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01967602.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01967602*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*